SCHEMBL2996936

SCHEMBL2996936

NNC(=O)c1ccnc(Cc2ccccc2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5B Q9UGL1 4/20 0.50
KDM5C P41229 2/20 0.50
KDM4A O75164 1/20 0.50
KDM4B O94953 1/20 0.50
BRD4 O60885 6/20 0.49
KDM5A P29375 2/20 0.47
KDM2B Q8NHM5 1/20 0.47
KDM4C Q9H3R0 1/20 0.47
KDM4E B2RXH2 3/20 0.46
MPO P05164 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
ADORA3 P0DMS8 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2A6 P11509 1/20 0.46
CYP2C19 P33261 1/20 0.46
LMNA P02545 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
HTT P42858 2/20 0.46
ALDH1A1 P00352 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4005621 0.87 KDM5B (0.51) KDM5BKDM5CKDM4AKDM4BKDM5A
SCHEMBL1569193 0.84 BRD4 (0.55) KDM5BKDM5CKDM4AKDM4BBRD4
SCHEMBL27925527 0.84 KDM4C (0.62) KDM5BKDM5CKDM4AKDM4BBRD4
SCHEMBL580585 0.81 KDM5B (0.56) KDM5BKDM5CKDM4AKDM4BBRD4
SCHEMBL15542772 0.80 NPC1 (0.57) KDM4ECYP1A2CYP3A4CYP2C19LMNA
SCHEMBL16267495 0.80 KDM4E (0.54) KDM4ELMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL16535337 0.78 CYP1A2 (0.61) KDM5BKDM5CKDM4AKDM4BBRD4
SCHEMBL2989555 0.78 CYP1A2 (0.60) KDM5BKDM5CKDM5AKDM4CKDM4E
SCHEMBL2989476 0.77 KDM4E (0.47) KDM5BKDM5CKDM5AKDM4EMPO
SCHEMBL11198747 0.76 PRSS1 (0.59) KDM4EMPOCYP2D6LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100184811-A1 ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS BRIDGE BIORESEARCH RIGHTS (JERSEY) LIMITED (GB) 2010-07-22 US disclosed
EP-2068873-A2 ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS Pharma 2100 (DK) 2009-06-17 EP disclosed
WO-2008031440-A2 ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS PHARMA 2100 (DK) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184811-A1 ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS ODC1, OTC, ACACB KDM5B 2703/4885KDM5C 1159/4885KDM4A 2893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.